ABB India secures new order from Reliance Life Sciences’ biopharma facility

21 Aug 2023 , 12:32 PM

Reliance Life Sciences has awarded ABB India a contract to deliver automation and control systems for its new biosimilars and plasma proteins manufacturing plants in Nashik, Maharashtra.

The scope includes full manufacturing process automation with ABB’s flagship Distributed Control System (DCS) Ability System 800xA, Remote I/O systems, Batch Recipe Management, and MES Integration.

Reliance Life Sciences will use ABB technology to achieve operational excellence, shorten time to market, and maintain stringent quality control of their manufacturing operations.

Reliance Life Sciences can lower the total cost of ownership by adopting ABB’s DCS running on the most recent Windows version. ABB’s DCS solution offers an integration platform for monitoring various plant parts and facilitating maintenance.

ABB’s multichannel remote I/O solutions will provide streamlined data communication, less wiring, decluttered the plant’s hardware footprint, improved space usage, and faster project execution. Because the installation is for a pharmaceutical production unit, the DCS would be supplied in accordance with US FDA 21 CFR Part 11, in order to meet the requisite standards.

RLS’ 160-acre Nashik site will feature plasma protein, biopharmaceutical, oncology medicine, and vaccine manufacturing operations.

At around 12.27 PM, ABB India was trading 0.43% higher at Rs 4,298 per piece, against the previous close of Rs 4,279.50 on NSE. The counter touched an intraday high of Rs 4,320.

For feedback and suggestions, write to us at [e-mail]